Cowen and Company’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-15,000
Closed -$70.5K 123
2024
Q3
$70.5K Buy
+15,000
New +$373K ﹤0.01% 314
2024
Q2
Sell
-83,000
Closed -$226K 651
2024
Q1
$226K Buy
+83,000
New +$1.84M 0.01% 232
2023
Q4
Sell
-5,500
Closed -$8.11K 617
2023
Q3
$8.11K Buy
+5,500
New +$115K ﹤0.01% 480
2021
Q3
Sell
-27,500
Closed -$8K 634
2021
Q2
$8K Buy
+27,500
New +$641K ﹤0.01% 547
2021
Q1
Sell
-15,000
Closed -$8K 563
2020
Q4
$8K Buy
+15,000
New +$314K ﹤0.01% 355

Other funds holding EXEL

Cowen and Company's EXEL Position: Q4 2024 in Review

Cowen and Company sold out of Exelixis (EXEL) in Q4 2024, closing a stake of 362 shares — an estimated $9.39K sold.

Cowen and Company first reported a position in EXEL in Q4 2020 and held it in 4 quarters. The position peaked at $2.22M in Q4 2023. 519 funds tracked by Wall St. Rank hold EXEL as of Q4 2024.

  • Cowen and Company reported no remaining Exelixis position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 362 Exelixis shares in Q4 2024, an estimated $9.39K.
  • Cowen and Company first reported a position in Exelixis in Q4 2020 and held it in 4 quarters.
  • Cowen and Company's Exelixis position peaked at $2.22M in Q4 2023.
  • 519 funds tracked by Wall St. Rank held Exelixis as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.